Properties of Slo1 K+ channels with and without the gating ring.
High-conductance Ca(2+)- and voltage-activated K(+) (Slo1 or BK) channels (KCNMA1) play key roles in many physiological processes. The structure of the Slo1 channel has two functional domains, a core consisting of four voltage sensors controlling an ion-conducting pore, and a larger tail that forms an intracellular gating ring thought to confer Ca(2+) and Mg(2+) sensitivity as well as sensitivity to a host of other intracellular factors. Although the modular structure of the Slo1 channel is known, the functional properties of the core and the allosteric interactions between core and tail are poorly understood because it has not been possible to study the core in the absence of the gating ring. To address these questions, we developed constructs that allow functional cores of Slo1 channels to be expressed by replacing the 827-amino acid gating ring with short tails of either 74 or 11 amino acids. Recorded currents from these constructs reveals that the gating ring is not required for either expression or gating of the core. Voltage activation is retained after the gating ring is replaced, but all Ca(2+)- and Mg(2+)-dependent gating is lost. Replacing the gating ring also right-shifts the conductance-voltage relation, decreases mean open-channel and burst duration by about sixfold, and reduces apparent mean single-channel conductance by about 30%. These results show that the gating ring is not required for voltage activation but is required for Ca(2+) and Mg(2+) activation. They also suggest possible actions of the unliganded (passive) gating ring or added short tails on the core.
Departments of Anatomy and Neurobiology and Genetics, Washington University School of Medicine in St. Louis, St. Louis, MO 63110.
Gonzalo
G
Budelli
Yanyan
Y
Geng
Alice
A
Butler
Karl L
KL
Magleby
Lawrence
L
Salkoff
D000818:Animals; D002118:Calcium / Q000378:metabolism; D006801:Humans; D015640:Ion Channel Gating / Q000187:drug effects / Q000502:physiology*; D007700:Kinetics; D051665:Kv1.4 Potassium Channel / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D051037:Large-Conductance Calcium-Activated Potassium Channel alpha Subunits / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D008274:Magnesium / Q000378:metabolism; D051379:Mice; D016297:Mutagenesis, Site-Directed; D009841:Oligonucleotides / Q000235:genetics; D009865:Oocytes / Q000378:metabolism; D018408:Patch-Clamp Techniques; D010455:Peptides / Q000494:pharmacology; D019789:Tetraethylammonium / Q000494:pharmacology; D014981:Xenopus
C494841:KCNMA1 protein, human; D051665:Kv1.4 Potassium Channel; D051037:Large-Conductance Calcium-Activated Potassium Channel alpha Subunits; D009841:Oligonucleotides; D010455:Peptides; D019789:Tetraethylammonium; C064719:iberiotoxin; D008274:Magnesium; D002118:Calcium
BK channel; Kv1.4; iberiotoxin; tetraethylammonium; β1 subunit